CentralCharts: Supercharge your portfolio with groundbreaking tools.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of N-able, Inc. (NYSE: NABL) and Encourages Shareholders to Contact the Firm for Additional Information PR Newswire PHILADELPHIA, June 1, 2024 PHILADELPHIA , June 1, 2024 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating N-able, Inc. (NYSE: NABL) on behalf of the company's shareholders. The investigation seeks to determine whether N-able and/or the company's officers and directors violated the securities laws or breached...

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 through June 4, 2024, in...

NON-REGULATORY PRESS RELEASE Oslo, June 1, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM ( NCT04382664 ), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. The late-breaking abstract can be found on the 2024 ASCO website:...

Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024 PR Newswire DUBLIN, June 1, 2024 Zanidatamab demonstrated a median overall survival (OS) of 15.5 months in patients with centrally confirmed immunohistochemistry (IHC) 2+ or 3+ and a median OS of 18.1 months in patients with IHC 3+ tumors With approximately two years of median follow-up, as of July 28, 2023...

Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting PR Newswire INDIANAPOLIS, June 1, 2024 Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with pembrolizumab that is well-suited to first-line lung cancer development INDIANAPOLIS , June 1, 2024 /PRNewswire/ -- Eli...